Clinical trial • Phase I • Cardiology

RO7763505 for Stable coronary artery disease

Phase I trial of RO7763505 for Stable coronary artery disease. 196 participants.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Stable coronary artery disease
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
19-01-2026
First CTIS Authorization Date
06-03-2026

Trial design

Phase I trial across 1 site in Netherlands.

Target Sample Size
196

Eligibility

Recruits 196 Vulnerable population selected; no consent/assent details available in source..

Vulnerable Population
Vulnerable population selected; no consent/assent details available in source.

Recruitment

Planned Sample Size
196
Recruitment Window Months
23

Geography

Total Number Of Sites
1
Total Number Of Participants
196

Netherlands

Earliest CTIS Part Ii Submission Date
19-02-2026
Latest Decision Or Authorization Date
06-03-2026
Processing Time Days
15
Number Of Sites
1
Number Of Participants
196

Sites

Site Name
Pharmaceutical Research Associates Group B.V.
Department Name
Program Management
Contact Person Name
Jart Oosterhaven
Contact Person Email
Jart.Oosterhaven@iconplc.com

Sponsor

Primary sponsor

Full Name
F. Hoffmann-La Roche AG
Organisation Type
Pharmaceutical company
Country Of Registered Address
Switzerland

Contract research organisations

Name
Pharmaceutical Research Associates Group B.V.
Responsibilities
Program Management; trial site contact (Jart Oosterhaven, Jart.Oosterhaven@iconplc.com, +31504022327)

Investigational products

Investigational Product Name
RO7763505

Related trials

Other published trials that may interest you.